|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 176.49 USD | +0.44% |
|
+1.33% | +28.20% |
| 09/07 | European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading | MT |
| 08/07 | Ascendis Pharma A/S to Share Its Latest Endocrinology Rare Disease Data At Endo 2025 | CI |
| Capitalization | 914.4Cr 1.07TCr 852.05Cr 787.95Cr 1.46TCr 92TCr 1.63TCr 10TCr 3.89TCr 43TCr 4.01TCr 3.93TCr 1,56500Cr | P/E ratio 2025 * |
-42.6x | P/E ratio 2026 * | 103x |
|---|---|---|---|---|---|
| Enterprise value | 972.8Cr 1.14TCr 906.46Cr 838.27Cr 1.56TCr 97TCr 1.73TCr 11TCr 4.14TCr 46TCr 4.26TCr 4.18TCr 1,66500Cr | EV / Sales 2025 * |
15.2x | EV / Sales 2026 * | 8.56x |
| Free-Float |
97.58% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Ascendis Pharma A/S
More recommendations
More press releases
More news
| 1 day | +0.44% | ||
| 1 week | +1.33% | ||
| Current month | +2.25% | ||
| 1 month | +2.40% | ||
| 3 months | +23.14% | ||
| 6 months | +36.61% | ||
| Current year | +28.20% |
| 1 week | 168.01 |  | 180 |
| 1 month | 166.84 | | 180.78 |
| Current year | 118.03 | | 183 |
| 1 year | 111.09 | | 183 |
| 3 years | 64.33 | | 183 |
| 5 years | 61.58 | | 183.98 |
| 10 years | 11.92 | | 183.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
CEO | Chief Executive Officer | 66 | 01/12/2007 |
Scott Smith
DFI | Director of Finance/CFO | 52 | 08/08/2016 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/05/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
BRD | Director/Board Member | 66 | 01/12/2007 |
Albert Cha
CHM | Chairman | 53 | 28/05/2021 |
Lisa Bright
BRD | Director/Board Member | 58 | 01/04/2017 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.44% | +1.33% | +28.51% | +88.54% | 1.06TCr | ||
| +1.21% | +1.90% | +12.84% | +0.60% | 4.99TCr | ||
| -0.90% | +3.22% | +73.51% | +34.25% | 3.03TCr | ||
| +1.42% | +5.74% | +4.18% | +11.14% | 2.83TCr | ||
| +2.17% | +0.53% | -22.30% | -24.53% | 2.8TCr | ||
| +1.54% | -0.07% | +29.84% | -21.96% | 1.25TCr | ||
| +1.02% | +1.31% | -53.73% | -30.23% | 1.2TCr | ||
| +1.23% | -0.19% | +17.83% | -5.21% | 1.04TCr | ||
| +2.04% | -2.25% | +70.29% | - | 1.01TCr | ||
| +2.27% | +2.10% | -21.67% | +109.44% | 922.46Cr | ||
| Average | +1.12% | -0.89% | +13.93% | +18.01% | 2.01TCr | |
| Weighted average by Cap. | +1.05% | -0.91% | +15.35% | +10.23% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 64Cr 75Cr 60Cr 55Cr 102.36Cr 6.41TCr 113.96Cr 713Cr 272.3Cr 3TCr 280.49Cr 274.74Cr 11TCr | 112.93Cr 131.99Cr 105.23Cr 97Cr 180.63Cr 11TCr 201.1Cr 1.26TCr 480.52Cr 5.29TCr 494.97Cr 484.82Cr 19TCr |
| Net income | -22Cr -26Cr -21Cr -19Cr -36Cr -2.25TCr -40Cr -250.01Cr -95Cr -1.05TCr -98Cr -96Cr -3.84TCr | 16Cr 19Cr 15Cr 14Cr 26Cr 1.64TCr 29Cr 181.98Cr 69Cr 764.86Cr 72Cr 70Cr 2.8TCr |
| Net Debt | 58Cr 68Cr 54Cr 50Cr 93Cr 5.85TCr 103.99Cr 650.6Cr 248.47Cr 2.73TCr 255.94Cr 250.7Cr 9.99TCr | 52Cr 61Cr 49Cr 45Cr 83Cr 5.22TCr 93Cr 580.21Cr 221.59Cr 2.44TCr 228.25Cr 223.57Cr 8.91TCr |
More financial data
* Estimated data
Employees
1,017
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/25/10 | 176.49 $ | +0.44% | 4,65,700 |
| 09/25/09 | 175.71 $ | +4.48% | 8,38,013 |
| 08/25/08 | 168.17 $ | -4.44% | 4,75,434 |
| 07/25/07 | 175.98 $ | +1.03% | 4,76,887 |
| 03/25/03 | 174.18 $ | +0.62% | 1,57,816 |
Delayed Quote Nasdaq, July 11, 2025 at 01:30 am IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
151.00EUR
Average target price
200.66EUR
Spread / Average Target
+32.88%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ASND Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition